Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18788060 | NANO-DELIVERY CARRIER FOR TARGETED TUMOR ADMINISTRATION AND APPLICATION THEREOF | July 2024 | November 2024 | Allow | 3 | 0 | 0 | No | No |
| 18732203 | COMPOSITIONS FOR TREATMENT OF DISCOGENIC PAIN, AND PROCESSES FOR MAKING AND USING THE SAME | June 2024 | December 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18665612 | IMMUNOMODULATING TREATMENTS OF BODY CAVITIES | May 2024 | December 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18609128 | DRIED NANOPARTICLE COMPOSITIONS | March 2024 | October 2024 | Allow | 7 | 1 | 0 | No | No |
| 18405670 | EYE DROP COMPOSITION | January 2024 | November 2024 | Allow | 10 | 1 | 0 | No | No |
| 18543199 | SOLID SUBSTRATES FOR PROMOTING CELL AND TISSUE GROWTH | December 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18524148 | HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENT | November 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18516052 | Solid Drug Tablets for Implantable Drug Delivery Devices | November 2023 | June 2025 | Allow | 18 | 1 | 0 | No | No |
| 18381351 | DISPENSER AND METHOD OF USE THEREOF | October 2023 | October 2024 | Allow | 11 | 0 | 0 | No | No |
| 18476396 | METHOD FOR TREATING A BIOLOGICALLY CONTAMINATED SURFACE | September 2023 | October 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18355360 | CONFORMAL COATING OF BIOLOGICAL SURFACES | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18221300 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | July 2023 | September 2024 | Allow | 15 | 1 | 0 | No | No |
| 18341337 | MICROBIOTA SEQUENCE VARIANTS OF TUMOR-RELATED ANTIGENIC EPITOPES | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18211938 | NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOF | June 2023 | May 2025 | Allow | 23 | 2 | 0 | No | No |
| 18201864 | ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOF | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18322417 | SINGLE- AND MIXED-METAL NANOPARTICLES, NANOPARTICLE CONJUGATES, DEVICES FOR MAKING NANOPARTICLES, AND RELATED METHODS OF USE | May 2023 | December 2024 | Allow | 19 | 2 | 0 | No | No |
| 18310706 | DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME | May 2023 | June 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18303530 | ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONSIVE BIOPOLYMER NETWORKS | April 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18134247 | METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERY | April 2023 | November 2024 | Allow | 19 | 1 | 0 | No | No |
| 18130336 | NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEM | April 2023 | February 2025 | Allow | 23 | 3 | 0 | No | No |
| 18121527 | TARGETING THE INNATE IMMUNE SYSTEM TO INDUCE LONG-TERM TOLERANCE AND TO RESOLVE MACROPHAGE ACCUMULATION IN ATHEROSCLEROSIS | March 2023 | February 2025 | Allow | 23 | 2 | 0 | No | No |
| 18176231 | DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME | February 2023 | June 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18172094 | [161Tb]-BASED RADIOPEPTIDES | February 2023 | September 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 18152137 | RADIOTHERAPY GEL AND METHOD OF PREPARING THE SAME | January 2023 | September 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18146158 | Nanostructured Surfaces | December 2022 | July 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18076772 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES | December 2022 | December 2024 | Allow | 24 | 2 | 0 | No | No |
| 17982116 | COMPOSITIONS OF HYPOCHLOROUS ACID AND METHODS OF MANUFACTURE THEREOF | November 2022 | March 2025 | Allow | 28 | 3 | 0 | Yes | No |
| 17857413 | MULTIMODAL SILICA-BASED NANOPARTICLES | July 2022 | July 2024 | Allow | 25 | 1 | 0 | No | No |
| 17842100 | ACETIC ACID AND HYPOCHLOROUS ACID COMPOSITIONS FOR TREATMENT OF SKIN TRAUMA | June 2022 | May 2025 | Allow | 35 | 5 | 0 | No | No |
| 17738647 | M13 PHAGE BASED GENE THERAPY PLATFORM | May 2022 | June 2025 | Allow | 38 | 0 | 0 | No | No |
| 17638559 | METHOD OF PREPARING A RADIOACTIVE YTTRIUM PHOSPHATE PARTICLE SUSPENSION | February 2022 | September 2024 | Allow | 31 | 3 | 0 | No | No |
| 17638512 | NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS | February 2022 | May 2025 | Allow | 39 | 0 | 0 | No | No |
| 17672998 | Compositions Comprising Milk Fat Globules | February 2022 | April 2025 | Abandon | 38 | 5 | 0 | Yes | No |
| 17566023 | Antimicrobial Solid Surfaces and Treatments and Processes for Preparing the Same | December 2021 | December 2024 | Allow | 35 | 4 | 0 | Yes | No |
| 17566335 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | December 2021 | January 2025 | Allow | 37 | 2 | 0 | No | Yes |
| 17620312 | BIOTHIOL-ACTIVATABLE PROBE AND METHOD OF USE | December 2021 | June 2025 | Allow | 42 | 2 | 0 | No | No |
| 17609536 | THERAPEUTIC PEPTIDES | November 2021 | June 2025 | Allow | 43 | 2 | 0 | No | No |
| 17521414 | THERAPEUTIC PROTEIN-BASED NANOPARTICLES FOR TREATING CANCER | November 2021 | December 2024 | Allow | 38 | 3 | 0 | Yes | No |
| 17517808 | Succinylcholine Chloride Prefilled Syringe | November 2021 | January 2025 | Allow | 38 | 5 | 0 | Yes | No |
| 17518353 | ANTI-PEST GUARDIAN BARRIER INCLUDING AN ARTICLE/SUBSTRATE PROTECTING DRYING OIL | November 2021 | November 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17451706 | TARGET DELIVERY OF CHEMICAL TRACERS FOR SINGLE WELL CHEMICAL TRACER TESTS | October 2021 | April 2025 | Abandon | 41 | 5 | 1 | Yes | No |
| 17603494 | FUNCTIONALIZED SILICA NANORINGS, METHODS OF MAKING SAME, AND USES THEREOF | October 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17469021 | Long-acting formulations | September 2021 | June 2024 | Allow | 34 | 3 | 0 | Yes | No |
| 17446386 | APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE | August 2021 | June 2025 | Allow | 45 | 3 | 1 | No | No |
| 17460235 | TARGETED MAGNETIC VEHICLES AND METHOD OF USING THE SAME | August 2021 | April 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17434363 | MODULAR METAL�ORGANIC POLYHEDRA SUPERASSEMBLY COMPOSITIONS | August 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
| 17424084 | PSMA LIGAND TARGETED COMPOUNDS AND USES THEREOF | July 2021 | June 2024 | Allow | 35 | 0 | 0 | No | No |
| 17341765 | APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE | June 2021 | November 2024 | Allow | 41 | 3 | 0 | No | No |
| 17294701 | RECONSTITUTED HDL NANOPARTICLES FOR DELIVERY OF RADIOACTIVE AGENTS AND USES THEREOF | May 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17322577 | MEDICAL IMAGING TECHNIQUE USING X-RAY TO NEAR-INFRARED DOWNCONVERTING NANOPOWDER | May 2021 | February 2025 | Allow | 45 | 1 | 1 | No | No |
| 17221959 | PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS | April 2021 | September 2024 | Allow | 42 | 3 | 1 | No | Yes |
| 17221203 | Catalytic Microgelators for Decoupled Control of Gelation Rate and Rigidity of Biological Gels | April 2021 | September 2024 | Allow | 41 | 5 | 0 | No | No |
| 17268952 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | February 2021 | September 2024 | Allow | 43 | 1 | 0 | No | No |
| 17263269 | METHOD FOR ANALYZING THE PLATELETS OF A BLOOD SAMPLE | January 2021 | November 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17263052 | BIOCOMPATIBLE ULTRASONIC COUPLING AGENT FOR ENDOSCOPE AND USE THEREOF | January 2021 | April 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17258846 | METHODS AND COMPOSITIONS FOR DELIVERY OF AGENTS ACROSS THE BLOOD-BRAIN BARRIER | January 2021 | May 2025 | Allow | 52 | 2 | 1 | No | No |
| 17047299 | NANOMOLECULES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | October 2020 | May 2025 | Allow | 55 | 3 | 0 | No | No |
| 17066418 | Magnetic Microwires for Energy-Transporting Biomedical Applications | October 2020 | March 2025 | Allow | 53 | 3 | 1 | No | No |
| 17027286 | FLUOROPHORES FOR SUPER-RESOLUTION IMAGING | September 2020 | June 2025 | Allow | 56 | 5 | 1 | Yes | Yes |
| 17018314 | TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | September 2020 | November 2024 | Allow | 50 | 5 | 0 | Yes | No |
| 16983171 | Method of enhancing the antimicrobial action of systemically administered antibiotics | August 2020 | August 2024 | Allow | 60 | 3 | 0 | Yes | No |
| 16936909 | STABLE COMPOSITIONS OF MRNA-LOADED LIPID NANOPARTICLES AND PROCESSES OF MAKING | July 2020 | June 2024 | Allow | 47 | 5 | 0 | No | No |
| 16960393 | COMPOSITIONS AND METHODS RELATING TO MACROPHAGES AND/OR MONOCYTES WITH ADHERED PARTICLES | July 2020 | May 2025 | Allow | 58 | 4 | 1 | No | No |
| 16761114 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | May 2020 | February 2025 | Allow | 58 | 3 | 0 | No | Yes |
| 16760215 | LIPOSOMAL FORMULATION OF BACTERIAL LIPOPOLYSACCHARIDE COMBINED WITH A CYTOTOXIC AGENT, AND USE THEREOF IN ANTI-TUMOUR THERAPY | April 2020 | June 2025 | Allow | 60 | 8 | 0 | Yes | No |
| 16719248 | POLYMERIC NANOPARTICULATE FORMULATION TO ENHANCE THE ORAL BIOAVAILABILITY OF DAPOXETINE | December 2019 | March 2020 | Allow | 3 | 1 | 0 | Yes | No |
| 16691678 | IN SITU GELLING COMPOSITION CONTAINING TOCOPHEROL-LOADED MICELLLES AS AN INTRANASAL DRUG DELIVERY SYSTEM | November 2019 | June 2020 | Allow | 7 | 1 | 0 | No | No |
| 16597861 | METHODS FOR REDUCING SIDE EFFECTS OF IMMUNOTHERAPY | October 2019 | December 2024 | Allow | 60 | 4 | 0 | No | No |
| 16513758 | STABLE MELPHALAN LIQUID INJECTABLE FORMULATIONS | July 2019 | February 2020 | Allow | 7 | 2 | 0 | No | No |
| 16344288 | PROMOTING HAIR GROWTH AND TREATMENT OF HAIR LOSS OR EXCESSIVE HAIR SHEDDING | April 2019 | December 2024 | Abandon | 60 | 10 | 0 | Yes | Yes |
| 16333558 | EXTRACELLULAR MATRIX MATERIAL | March 2019 | December 2024 | Allow | 60 | 6 | 0 | Yes | Yes |
| 16240918 | PERFORATED CAPSULES | January 2019 | April 2025 | Abandon | 60 | 10 | 0 | No | No |
| 16030068 | COMPOSITION FOR URIC ACID DECOMPOSITION USING GOLD NANOPARTICLES | July 2018 | September 2019 | Allow | 14 | 0 | 0 | No | No |
| 15968133 | ANIMAL FEED COMPOSITIONS AND FEED ADDITIVES | May 2018 | April 2019 | Allow | 12 | 1 | 0 | No | No |
| 15864679 | METHODS OF PREPARING OPHTHALMIC FORMULATIONS AND USES OF SAME | January 2018 | March 2019 | Allow | 14 | 2 | 0 | No | No |
| 15548151 | HIGH-RESOLUTION OPTICAL MOLECULAR IMAGING SYSTEMS, COMPOSITIONS, AND METHODS | August 2017 | March 2020 | Allow | 31 | 2 | 0 | Yes | No |
| 15545058 | STENT HAVING FUNCTIONAL MATERIAL COATED ON CELL SPACE THEREOF | July 2017 | August 2019 | Allow | 25 | 1 | 0 | No | No |
| 15484691 | METHODS, COMPOSITIONS AND KITS FOR PROVIDING A THERAPEUTIC TREATMENT | April 2017 | April 2019 | Allow | 24 | 3 | 0 | No | No |
| 15077434 | USE OF POLYSACCHARIDES IN ANTIPERSPIRANT COSMETIC AGENTS FOR PROTECTING TEXTILES | March 2016 | February 2020 | Allow | 47 | 5 | 0 | No | No |
| 14812598 | ANIMAL FEED COMPOSITIONS AND FEED ADDITIVES | July 2015 | February 2018 | Allow | 30 | 2 | 0 | No | No |
| 14803673 | METAL-METAL BORIDE-METAL BASED CORE-SHELL PARTICLES AND A METHOD TO PRODUCE THE SAME | July 2015 | May 2019 | Allow | 46 | 4 | 0 | No | No |
| 14539357 | COMPOSITIONS FOR DELIVERY OF ORAL COMFORT SENSATIONS | November 2014 | June 2017 | Allow | 31 | 2 | 0 | Yes | No |
| 14398115 | FLUORECSCENT, SPHERICAL SOPHOROLIPID MESOSTRUCTURES FOR IMAGING AND THERAPEUTIC APPLICATIONS | October 2014 | March 2017 | Allow | 29 | 2 | 0 | No | No |
| 14240081 | APOPTOSIS-TARGETING NANOPARTICLES | May 2014 | June 2017 | Allow | 40 | 4 | 0 | Yes | No |
| 14357928 | CATIONIC ANTIBACTERIAL COMPOSITION | May 2014 | January 2018 | Allow | 44 | 3 | 0 | Yes | No |
| 14234548 | Glycolate Formulation for Preserving Wood and Like Materials | May 2014 | April 2016 | Allow | 27 | 2 | 0 | Yes | No |
| 14355618 | COSMETIC PREPARATION COMPRISING PULVERIZED HYDROPHILIC SUBSTANCES | May 2014 | April 2018 | Allow | 47 | 2 | 0 | No | Yes |
| 14355616 | COSMETIC PREPARATION COMPRISING PULVERIZED HYDROPHOBIC SUBSTANCES | May 2014 | November 2018 | Abandon | 55 | 2 | 0 | No | Yes |
| 14175422 | NANOPARTICLE DELIVERY COMPOSITIONS | February 2014 | January 2019 | Allow | 59 | 4 | 2 | No | No |
| 13879408 | SILICA NANOPARTICLES DOPED WITH MULTIPLE DYES FEATURING HIGHLY EFFICIENT ENERGY TRANSFER AND TUNABLE STOKES-SHIFT | August 2013 | November 2016 | Allow | 44 | 2 | 0 | No | No |
| 13800480 | Polymorph Compositions, Methods of Making, and Uses Thereof | March 2013 | March 2016 | Allow | 36 | 1 | 1 | Yes | No |
| 13773718 | METHODS OF USING MULTILAYER MAGNETIC MICELLE COMPOSITIONS | February 2013 | June 2017 | Allow | 51 | 3 | 0 | Yes | No |
| 13647308 | MICRONIZED COMPOSITIONS COMPOSED OF BONE GRAFTS AND METHODS OF MAKING AND USING THE SAME | October 2012 | December 2024 | Allow | 60 | 12 | 1 | No | No |
| 13578458 | LIQUID-FILLED PROTEIN-PHOSPHATIDIC ACID CAPSULE DISPERSIONS | August 2012 | December 2013 | Allow | 16 | 1 | 1 | Yes | No |
| 13503978 | ANTI-CANCER COMPOSITION COMPRISING ALGINATE | July 2012 | May 2016 | Allow | 49 | 5 | 1 | Yes | No |
| 13277288 | LOW VOLATILE REACTIVE MALODOR COUNTERACTIVES AND METHODS OF USE THEREOF | October 2011 | August 2013 | Abandon | 22 | 3 | 1 | Yes | No |
| 13259228 | PROCESS FOR MAKING STABLE HIGH VISCOSITY AMINO SILICONE EMULSION | September 2011 | October 2015 | Allow | 49 | 4 | 1 | No | No |
| 12991338 | Opioid Composition for Treating Skin Lesions | September 2011 | May 2017 | Allow | 60 | 7 | 0 | Yes | Yes |
| 13198658 | CYCLOSILOXANE-SUBSTITUTED POLYSILOXANE COMPOUNDS, COMPOSITIONS CONTAINING THE COMPOUNDS AND METHODS OF USE THEREOF | August 2011 | June 2015 | Allow | 46 | 5 | 0 | Yes | No |
| 13142730 | Innately Multimodal Nanoparticles | June 2011 | June 2013 | Allow | 24 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CABRAL, ROBERT S.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CABRAL, ROBERT S works in Art Unit 1614 and has examined 105 patent applications in our dataset. With an allowance rate of 89.5%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.
Examiner CABRAL, ROBERT S's allowance rate of 89.5% places them in the 69% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by CABRAL, ROBERT S receive 2.78 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CABRAL, ROBERT S is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -1.0% benefit to allowance rate for applications examined by CABRAL, ROBERT S. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 24.7% of applications are subsequently allowed. This success rate is in the 27% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 36.5% of cases where such amendments are filed. This entry rate is in the 47% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 37.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.